EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Shares of Editas Medicine (EDIT) plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its lead gene editing therapy, reni-cel, which is being developed for certain non-malignant hematologic diseases, or potentially out-license rights to the treatment entirely, amid a significant cash crunch. Editas firmly believes that this decision is in the best interests of its patients and shareholders, as a potential partnership agreement would allow for further development and ultim ...